Pre-Approval Information Exchange Act of 2022
Summary
Pre-Approval Information Exchange Act of 2022 This bill specifies that product information that is exchanged between drug manufacturers and certain health care entities (e.g., formulary committees) about drug products before regulatory approval is not considered to be misbranding if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.
Bill status
in committee
1 of 4 stages cleared
Introduction
Nov 2022
Committee Review
Floor Vote
President
Introduced Nov 15, 2022
Last action Nov 16, 2022
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
2
Nov 16, 2022
Committee
Referred to the Subcommittee on Health.
lower
Nov 15, 2022
Committee
Referred to the House Committee on Energy and Commerce.
lower
Nov 15, 2022
Introduced
Introduced in House
lower
1 primary · 5 co-sponsors
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 9297
Scope: US
Hi! I can help you understand HR 9297. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline